# SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct03262935/  
OnCo record `nct03262935` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab duocarmazine, Lapatinib, Capecitabine, Trastuzumab, Vinorelbine and Eribulin in Breast cancer, run by Byondis B.V., completed.

## Summary

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT03262935 by Byondis B.V., with 437 participants recorded, started 2017-12-15 and reaching its primary completion in 2021-03-31. Interventions recorded: (vic-)trastuzumab duocarmazine, Physician's choice. Conditions recorded: Metastatic Breast Cancer.

Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03262935
- Phase: 3
- Setting: A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Sponsor: Byondis B.V.
- Enrolled: 437

## Sources

- ClinicalTrials.gov NCT03262935: https://clinicaltrials.gov/study/NCT03262935

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Eribulin](https://onco.cc/drugs/eribulin/), [Lapatinib](https://onco.cc/drugs/lapatinib/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab duocarmazine](https://onco.cc/drugs/trastuzumab-duocarmazine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Byondis](https://onco.cc/companies/byondis/)

---
JSON: https://onco.cc/api/v1/entities/nct03262935.json